β受体阻滞剂在冠心病合并糖尿病患者中的应用研究  

Application of β Adrenergic Blocker in Patients with Diabetes Accompanied with Coronary Heart Diseases

作　　者：王军[1] 陈玲[2] 靳雪松[3] 

机构地区：[1]中国人民解放军61195部队武汉干休所 [2]中国人民解放军第161医院 [3]中国人民解放军61195部队卫生处

出　　处：《中国医药指南》2016年第36期11-12,共2页Guide of China Medicine

摘　　要：目的探讨冠心病合并糖尿病患者应用β受体阻滞剂治疗的效果。方法选取我门诊部收治的糖尿病合并冠心病患者116例,将其随机分为对照组(58例)和观察组(58例),两组患者分别采用美托洛尔和拉贝洛尔治疗,观察两组患者的治疗效果。结果观察组对血脂和血糖代谢的影响,明显优于对照组(P<0.05)。观察组患者不良反应的发生率为17.24%,明显低于对照组的41.38%(P<0.05)。结论拉贝洛尔能有效改善冠心病合并糖尿病患者的血脂和血糖水平,效果安全可靠。Objective To explore the effect of β adrenergic blocker in patients with diabetes accompanied with coronary heart diseases. Methods A total of 116 patients with diabetes mellitus complicated with coronary heart disease patients were randomly divided into two groups, control group（58 cases） and observation group（58 cases）. Metoprolol and labetalol were used respectively in two groups. Results The effect of the observation group on blood lipid and glucose metabolism was significantly better than that of the control group（P〈0.05）. The incidence of adverse reactions in observation group was 41.38%, which was significantly lower than that of the control group 17.24%（P〈0.05）. Conclusion Labetalol can effectively improve the diabetes mellitus complicated with coronary heart disease patients＇ blood lipid and glucose levels.

关 键 词：Β受体阻滞剂 糖尿病 血糖 

分 类 号：R587.1[医药卫生—内分泌] R541.4[医药卫生—内科学]